Modality
Linear peptide
Unmodified or minimally modified peptide chains, often requiring parenteral delivery due to gut lability.
Examples
- Semaglutide
- Tirzepatide
- Retatrutide
- Pemvidutide
Related assets
View all →| Asset | Stage | Mechanism |
|---|---|---|
| Semaglutide | Approved | Long-acting GLP-1 receptor agonist with amino-acid substitutions and fatty-acid side chain for albumin binding. |
| Retatrutide | Phase 3 | Once-weekly triple agonist of GLP-1, GIP, and glucagon receptors in development for obesity and related conditions. |
| Mazdutide | Phase 3 | OXM-derived dual GLP-1 and glucagon receptor agonist licensed from Eli Lilly and developed in China. |
| Pemvidutide | Phase 2 | Novel dual GLP-1 and glucagon receptor agonist peptide with a pulmonary-shunt stabilizing albumin binder. |
| Efinopegdutide | Phase 2 | Pegylated dual GLP-1/glucagon receptor agonist peptide evaluated in NASH/MASH and metabolic disease. |